Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03611621
Other study ID # 17-HMedIdeS-14
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 27, 2018
Est. completion date February 14, 2023

Study information

Verified date February 2023
Source Hansa Biopharma AB
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome for these subjects. Data of parameters such as patient and graft survival, comorbidity, treatment of graft rejection episodes and quality of life as well as anti-drug antibody levels will be collected. This prospective, observational follow up study of subjects who have received imlifidase prior to kidney transplantation will provide important data to future prescribers and patients of the potential long-term benefits of imlifidase mediated transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date February 14, 2023
Est. primary completion date February 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed Informed Consent obtained before any study-related procedures - Previous dosing with imlifidase followed by kidney transplantation and participation in one of the following clinical studies: 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS-04 or 15-HMedIdeS-06 Exclusion Criteria: - Individuals deemed unable to comply with the protocol - Inability by the judgment of the investigator to participate in the study for other reasons

Study Design


Related Conditions & MeSH terms

  • Kidney Transplant Failure and Rejection

Intervention

Drug:
Imlifidase
This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.

Locations

Country Name City State
France Necker Hospital Paris
Sweden Karolinska University Hospital Stockholm
Sweden Uppsala University Hospital Uppsala
United States The Johns Hopkins Hospital Baltimore Maryland
United States Cedars-Sinai Medical Center Los Angeles California
United States New York University School of Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
Hansa Biopharma AB

Countries where clinical trial is conducted

United States,  France,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of graft survival in subjects who have undergone kidney transplantation after imlifidase administration. The primary endpoint of this study is to determine overall graft survival, defined as time from transplantation to graft loss. 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of patient survival. Overall patient survival defined as time from transplantation to death for any cause 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of kidney function (eGFR). Kidney function as evaluated by eGFR 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of kidney function (P-creatinine). Kidney function as evaluated by P-creatinine 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of kidney function (proteinuria). Kidney function as evaluated by proteinuria 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of number of graft rejection episodes. Record graft rejection episodes (classified by Banff, Haas et al 2018) 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of treatment of graft rejection episodes. Record graft rejection episodes treatments 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of comorbidities. Record comorbidities 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of treatments of comorbidities. Record concomitant immunosuppressive medication 5 years after first dose of imlifidase
Secondary Assessment of safety laboratory testing in terms of hematology (Hb) Blood samples will be analysed for hemoglobulin (Hb) 5 years after first dose of imlifidase
Secondary Assessment of safety laboratory testing in terms of hematology (differential analysis of leucocytes) Differential analysis of leucocytes will be done in blood samples 5 years after first dose of imlifidase
Secondary Assessment of safety laboratory testing in terms of hematology (thrombocytes) Blood samples will be analysed for thrombocytes 5 years after first dose of imlifidase
Secondary Assessment of safety laboratory testing in terms of total IgG Blood samples will be analysed for total IgG levels. 5 years after first dose of imlifidase
Secondary Assessment of donor specific antibodies (DSA) DSA levels in blood samples will be analysed by SAB-HLA 5 years after first dose of imlifidase
Secondary Assessment of the presence of BK virus Blood samples will be analysed for antibodies towards BK virus 5 years after first dose of imlifidase
Secondary Assessment of the immunogenicity of imlifidase Serum samples will be analysed for anti-drug antibody (ADA) levels using an ImmunoCAP assay. 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of quality of life (EQ-5D-5L). Health related quality of life (HR-QoL) as evaluated by patient questionnaires EQ-5D-5L 5 years after first dose of imlifidase
Secondary Evaluation of long-term clinical outcomes of transplanted subjects treated with imlifidase in terms of quality of life (KDQOL-SF). Health related quality of life (HR-QoL) as evaluated by patient questionnaires KDQOL-SF 5 years after first dose of imlifidase
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04057742 - AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
Recruiting NCT03465397 - Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients Phase 4
Completed NCT03437577 - Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients Phase 1/Phase 2
Not yet recruiting NCT05282966 - Assessment of QSantâ„¢ for Underlying Allograft Rejection
Recruiting NCT04388930 - The Microbiota in Kidney Donation and Transplantation
Recruiting NCT05397821 - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Completed NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection
Active, not recruiting NCT05806749 - Immunological Tolerance in Patients With Mismatched Kidney Transplants Phase 1
Recruiting NCT04936282 - Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Phase 4
Enrolling by invitation NCT05285878 - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Phase 2
Recruiting NCT04526431 - Tacrolimus Pharmacokinetic Subpopulations
Active, not recruiting NCT03511560 - Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation Phase 4
Recruiting NCT03438773 - Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients Phase 1
Completed NCT05388955 - Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Completed NCT06394596 - Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
Completed NCT04413916 - MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
Completed NCT03466775 - Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes N/A
Active, not recruiting NCT04733131 - Long-term Outcomes After Conversion to Belatacept
Active, not recruiting NCT03380962 - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Phase 1/Phase 2
Active, not recruiting NCT04154267 - Protocol Biopsies in High-risk Renal Transplant Recipients N/A